The Relation of a Circulating Sodium Transport Inhibitor (the Natriuretic Hormone?) to Hypertension
Overview
Authors
Affiliations
It is proposed that in essential hypertension the underlying genetic lesion is a renal difficulty in excreting sodium, which becomes more apparent the higher the sodium intake. It is further proposed that the renal lesion is the cause of the observed rise in the plasma's capacity to inhibit Na+-K+-ATPase and that the inhibitor's action on vascular smooth muscle eventually leads to the rise in blood pressure.
Erythrocyte sodium/potassium ATPase activity in severe preeclampsia.
Adair C, Haupert Jr G, Koh H, Wang Y, Veille J, Buckalew V J Perinatol. 2009; 29(4):280-3.
PMID: 19158804 PMC: 3065371. DOI: 10.1038/jp.2008.223.
Dupont A Cardiovasc Drugs Ther. 1993; 7 Suppl 1:55-62.
PMID: 8435377 DOI: 10.1007/BF00877958.
Correlative factors of left ventricular hypertrophy in end-stage renal disease.
Dai Y, He S, Yu Y, Zhu L, Peng B, Liu J J Tongji Med Univ. 1993; 13(4):252-6.
PMID: 8151747 DOI: 10.1007/BF02888021.
New approaches in treatment of hyponatremia.
Menon R Indian J Pediatr. 1985; 52(418):448-50.
PMID: 4077187 DOI: 10.1007/BF02751012.
Macgregor G Br J Clin Pharmacol. 1986; 21 Suppl 2:123S-128S.
PMID: 3530296 PMC: 1400733. DOI: 10.1111/j.1365-2125.1986.tb02861.x.